Security Snapshot

TRXADE HEALTH INC - COM NEW (MEDS) Institutional Ownership

CUSIP: 89846A207

13F Institutional Holders and Ownership History from Q1 2020 to Q3 2023

13F reference period

n/a

Institutions Reporting

Shares (Excl. Options)

n/a

Price

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • MEDS - TRXADE HEALTH INC - COM NEW is tracked under CUSIP 89846A207.
  • 13F reference-period holder data is not available.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder data for the Q2 2026 reference period is not available.
  • Available periods remain in the history table; they do not substitute for the headline period.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

89846A207

13F reference period

n/a

13F holders

13D/G owners

0

CIK / CUSIP context first

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
15
Headline period
n/a
Rows shown
1-15 of 15
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2023 Q3 0 $0 -$2,000 0
2023 Q2 5,354 $2,000 -$67,238 $0.37 1
2023 Q1 235,397 $69,238 -$269,331 $0.30 11
2022 Q4 927,864 $376,024 +$128,102 $0.40 13
2022 Q3 579,309 $658,000 -$14,251 $1.13 12
2022 Q2 585,839 $951,000 +$42,206 $1.61 11
2022 Q1 537,475 $1,489,000 -$266,199 $2.77 12
2021 Q4 643,711 $1,516,000 +$219,858 $2.34 13
2021 Q3 526,475 $2,594,000 +$116,653 $4.93 8
2021 Q2 509,165 $2,251,000 -$3,286,578 $4.42 10
2021 Q1 1,113,516 $5,833,888 +$2,464,777 $5.24 13
2020 Q4 637,880 $3,374,000 -$2,269,370 $5.29 13
2020 Q3 1,062,394 $6,639,000 +$2,261,913 $6.25 8
2020 Q2 700,542 $4,232,000 +$1,484,808 $6.01 9
2020 Q1 453,576 $2,608,000 +$2,608,000 $5.74 5
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .